Navigation Links
Lentigen Corporation and PATH Announce Partnership on Innovative Vaccine for Pandemic Influenza
Date:12/4/2008

Partnership will accelerate research of potential vaccine for low-resource countries

SEATTLE, and GAITHERSBURG, Md., Dec. 4 /PRNewswire/ -- The biotech company Lentigen Corporation and the nonprofit global health organization PATH announced today a partnership to accelerate research on a pandemic influenza vaccine. PATH will initially invest $3 million over 27 months and work with Lentigen on early-stage development of a H5N1 virus-like particle (VLP) prototype pandemic influenza vaccine.

With global health leaders increasingly concerned about the possibility of an influenza pandemic, PATH is working with public- and private-sector partners to advance the development of new, safe, and effective influenza vaccines that can be produced quickly and economically in large quantities to combat a global influenza pandemic, especially in low-income countries.

Vaccines based on VLPs can overcome many of the limitations of traditional influenza vaccines by offering highly immunogenic, strain-specific recombinant antigens that can be produced economically and at large scale. VLPs are self-assembling particles that can be made in cell culture, avoiding the need to rely on limited egg supplies for vaccine production. The Lentigen process may have unique advantages by producing high yields of VLPs in a portable and disposable manufacturing system.

"We are delighted to partner with Lentigen," commented Dr. Kathleen Neuzil, director of PATH's Influenza Vaccine Development Project. "Lentigen's technology is versatile and economical, and could be transferred to manufacturers in multiple locations to achieve our goal of developing a pandemic influenza vaccine to meet the needs of people in low-resource countries."

"The rapid development, production, and distribution of pandemic influenza vaccines could potentially save millions of lives in parts of the world that may not otherwi
'/>"/>

SOURCE Lentigen Corporation
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3

Related biology technology :

1. Lentigen Corporation Announces Relocation to New Facility
2. Lentigen Appoints Jim Meade as Vice President of Corporate Development
3. Lentigen Corporation Receives Four Research Grants From the National Institutes of Health
4. Lentigen Licenses Fundamental Lentiviral Vector Technology Patent From the University of Cambridge
5. Lentigen Corporation Announces Exclusive Licensing Agreement With Case Western Reserve University to Develop Novel Stem-Cell Therapy for Brain Cancer
6. Lentigen to Move Headquarters and Manufacturing to Gaithersburg
7. Lentigen Appoints Tim Ravenscroft as Chief Executive Officer
8. VIRxSYS and Lentigen Announce Litigation Settlement
9. Met-Pro Corporation Declares Quarterly Dividend
10. China Medicine Corporation Awarded GSP Certification
11. Convey Computer™ Corporation Announces First Customer: University of California, San Diego at SC08 Conference
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/30/2014)... PARIS , July 30, 2014  Regeneron ... NYSE: SNY) today announced that the Companies intend to ... pediatric disease priority review voucher in connection with the ... review voucher entitles the holder to designate a BLA ... review from the filing date instead of the standard ...
(Date:7/30/2014)... 30, 2014  Replikins Ltd. today released new data ... virus. Before the current outbreaks, the mean Ebola Reston ... acids) between 1995 and 2002 was 1.1; the mean ... and sixteen-fold in 2013, thus predicting the current outbreaks ... has been shown to be able to predict outbreaks ...
(Date:7/30/2014)... With the accelerated aging of the ... as well as the improved medical care facilities ... industry has been developing quickly, especially in vitro ... in vitro diagnostics market size reached RMB22.98 billion, ... diagnostic reagents. , Read complete report with ...
(Date:7/30/2014)... July 30, 2014  Orexigen Therapeutics, Inc. (Nasdaq: ... Day 180 List of Outstanding Issues (LOI) from the ... Use (CHMP) for the NB32 Marketing Authorization Application (MAA). ... an investigational drug candidate being evaluated for weight loss. ... 120 time point were adequately addressed by the Company ...
Breaking Biology Technology:Regeneron and Sanofi Announce Plan to Use Priority Review Voucher For Alirocumab U.S. FDA Submission 2Regeneron and Sanofi Announce Plan to Use Priority Review Voucher For Alirocumab U.S. FDA Submission 3Regeneron and Sanofi Announce Plan to Use Priority Review Voucher For Alirocumab U.S. FDA Submission 4Regeneron and Sanofi Announce Plan to Use Priority Review Voucher For Alirocumab U.S. FDA Submission 5Regeneron and Sanofi Announce Plan to Use Priority Review Voucher For Alirocumab U.S. FDA Submission 6China Diagnostic Reagent Industry Report, 2013-2016 | Researchmoz 2China Diagnostic Reagent Industry Report, 2013-2016 | Researchmoz 3Orexigen Receives CHMP Day 180 List of Outstanding Issues 2Orexigen Receives CHMP Day 180 List of Outstanding Issues 3
... 2012  Foundation for Health Improvement and Technology (FHIT), ... its nonprofit, with the mission to rid the ... through educational programs promoting early detection and aggressive ... research have made it entirely possible to detect ...
... Francisco, CA (March 14, 2012): A highly targeted ... O104 strain was rapidly created using AvidBiotics, antibacterial ... published, draft genomic sequence data as detailed in a ... strategy described offers a rapid-response platform with the potential ...
... of a specialist field to identify subject experts and ... bewildering. New research, published in BioMed Central,s open access ... method of social network analysis, similar to finding friends ... news articles to identify opinion leaders and media experts. ...
Cached Biology Technology:Foundation for Health Improvement and Technology (FHIT) Launched to Beat Cardiovascular Disease 2Targeted antibacterial agent rapidly created in response to serious food safety pathogen 2Targeted antibacterial agent rapidly created in response to serious food safety pathogen 3Social networking shortcut to finding medical experts 2
(Date:7/30/2014)... Press Limited today announced an across-the-board increase in ... The 2013 InCites Journal Citation Reports (Thomson Reuters, ... Biochemical Journal , Essays in Biochemistry , ... Reports all received increases in their Impact ... Society and published by Portland Press Limited. , ...
(Date:7/30/2014)... State University,s College of Engineering recently received a ... the project, "Nanoparticle-directed synthesis of organic nanorods." ... is the creation and utilization of functional materials, ... A major bottleneck in scaling up nanotechnology is ... functional materials into one device. A research team ...
(Date:7/30/2014)... Embryonic stem cells can develop into a multitude of cells ... development into the specific types of mature cells that make ... , One key seems to be long chains of sugars ... Godula,s group at the University of California, San Diego, has ... sugars, but can be more easily manipulated to direct the ...
Breaking Biology News(10 mins):Across-the-board Impact Factor increases for Portland Press Limited 2NSF grant to Wayne State supports new concept for manufacturing nanoscale devices 2
... New South Wales (UNSW) researchers have announced they are developing ... to treat a diverse range of health problems, from inflammation ... is published in the July issue of Nature Biotechnology. ... age-related macular degeneration (AMD) and diabetic retinopathy are likely to ...
... Physicians and surgeons will someday monitor a patient's blood ... thanks to research being conducted by a Cornell University ... new technology is being developed by Edwin Kan, associate ... Transonic Systems of Ithaca. Kan performed much of his ...
... factors that would explain the different life expectancies of ... universal, according to University of Michigan researchers. , "Women ... difference in lifespan has been recognized since at least ... scientist in the U-M School of Public Health and ...
Cached Biology News:'Molecular assassin' targets disease gene 2Researchers to develop ultra-miniature implantable sensors to measure blood flow 2Evolutionary forces explain why women live longer than men 2